Poor pregnancy outcome and anticardiolipin antibodies.
The present study reports for the first time on the presence of anticardiolipin antibodies (aCL) in a population of 259 women with a history of recurrent abortion, intrauterine death, and/or neonatal death associated with fetal growth restriction, preeclampsia and abruptio placentae. The overall incidence of aCL in this study group was 20.5%, a statistically significant increase in comparison with a control group. The highest positive rate was observed among women who presented both recurrent abortion and intrauterine death (33.3%), the lowest was observed among women with a history of neonatal death. Our findings confirm that aCL are strongly linked with fetal loss. Thus, before planning a subsequent pregnancy, the presence of aCL should be tested in all women with poor pregnancy outcome.
De Carolis
S
S
Department of Obstetrics and Gynecology, Catholic University, Rome, Italy.
Caruso
A
A
Ferrazzani
S
S
Carducci
B
B
De Santis
L
L
Mancuso
S
S
D000026:Abortion, Habitual / Q000276:immunology; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D005260:Female; D005313:Fetal Death / Q000276:immunology; D005317:Fetal Growth Retardation / Q000276:immunology; D006801:Humans; D010922:Placenta Diseases / Q000276:immunology; D011225:Pre-Eclampsia / Q000276:immunology; D011247:Pregnancy; D011256:Pregnancy Outcome
D017153:Antibodies, Anticardiolipin